Events

Join Seth Wander, MD, PhD, Mass General, and Elena Michaels, MD, Mass General and Dana-Farber Cancer Institute, for a discussion on how genomic sequencing is reshaping the understanding and treatment of ER-positive breast cancer. This session will explore key molecular drivers of resistance, the role of tumor sequencing in identifying actionable alterations, and the emerging therapies and drug targets transforming treatment strategies across the disease continuum.